Tacita Capital’s Gilead Sciences GILD Stock Holding History

Tacita Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-955	Closed	-$70K	–	216
2024 Q1	$70K	Hold	955	–	–	0.05%	124
2023 Q4	$77.4K	Sell	955 -225	-19%	-$17.5K	0.06%	110
2023 Q3	$88.4K	Buy	1,180 +225	+24%	+$17.3K	0.07%	106
2023 Q2	$74K	Hold	955	–	–	0.05%	112
2023 Q1	$79K	Hold	955	–	–	0.06%	101
2022 Q4	$82K	Sell	955 -45	-5%	-$3.56K	0.06%	99
2022 Q3	$62K	Hold	1,000	–	–	0.05%	103
2022 Q2	$62K	Buy	1,000 +685	+217%	+$42.4K	0.04%	117
2022 Q1	$19K	Buy	+315	New	+$20.1K	0.01%	180
2021 Q2	–	Sell	-150	Closed	-$10K	–	190
2021 Q1	$10K	Sell	150 -750	-83%	-$48.4K	0.01%	176
2020 Q4	$52K	Buy	+900	New	+$54.3K	0.03%	146

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tacita Capital's GILD Position: Q2 2024 in Review

Tacita Capital sold out of Gilead Sciences (GILD) in Q2 2024, closing a stake of 955 shares — an estimated $70K sold.

Tacita Capital first reported a position in GILD in Q4 2020 and held it in 11 quarters. The position peaked at $88.4K in Q3 2023. 1,678 funds tracked by Wall St. Rank hold GILD as of Q2 2024.

Tacita Capital reported no remaining Gilead Sciences position as of Q2 2024 after selling out during the quarter.
Tacita Capital sold 955 Gilead Sciences shares in Q2 2024, an estimated $70K.
Tacita Capital first reported a position in Gilead Sciences in Q4 2020 and held it in 11 quarters.
Tacita Capital's Gilead Sciences position peaked at $88.4K in Q3 2023.
1,678 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2024.

Based on Tacita Capital's 13F filing for Q2 2024, filed 8 Aug 2024.